Novartis AG (NVS) and Novavax, Inc. (NVAX)'s Experimental Bird Flu Vaccines Show Promise In Early Trials
11/14/2013 7:55:00 AM
The first human tests of experimental vaccines against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, has produced protective antibodies in the vast majority of recipients.
Encouraging results in early-stage trials were announced for separate vaccines from Swiss drugmaker Novartis and Novavax, a biotech company based in Rockville, Maryland.
Help employers find you! Check out all the jobs and post your resume.
comments powered by